Medicare Enrolled
Dr. Leo Orr, M.D.
Hematology & Oncology · Los Angeles, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Orr from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Orr?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Orr
Dr. Leo Orr is a hematology & oncology specialist in Los Angeles, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Orr performed 6,669 Medicare services across 627 unique beneficiaries.
Between the years covered by Open Payments, Dr. Orr received a total of $16,377 from 77 pharmaceutical and/or device companies across 708 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Orr is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 31% volume in CA
$16,377 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,669
Medicare services
Top 31% in CA for hematology & oncology
627
Unique beneficiaries
$24
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~351 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 4,560 | $18 | $46 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
390 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 328 | $0 | $0 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
247 | $96 | $268 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
189 | $12 | $31 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
179 | $8 | $13 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
106 | $90 | $140 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
98 | $68 | $188 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
93 | $1 | $2 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
70 | $65 | $172 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
68 | $55 | $149 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
67 | $147 | $382 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
63 | $12 | $36 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
57 | $25 | $66 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
45 | $66 | $163 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
44 | $118 | $302 |
| Assessment of emotional or behavioral problems An evaluation to identify and understand emotional or behavioral issues. This process involves reviewing symptoms and behaviors to determine the nature of the concerns. |
27 | $4 | $9 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
20 | $145 | $381 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
18 | $111 | $352 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.5% high complexity
85.4% medium
12.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,377
Total received (2018-2024)
Avg $2,340/year across 7 years
Top 25% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
77
Companies
708
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,267 (93.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$860 (5.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$250 (1.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,869
2023
$2,752
2022
$3,153
2021
$2,285
2020
$1,433
2019
$1,479
2018
$1,406
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$413
PFIZER INC.
$272
Janssen Biotech, Inc.
$256
Merck Sharp & Dohme LLC
$248
Daiichi Sankyo Inc.
$244
Bayer Healthcare Pharmaceuticals Inc.
$217
Eisai Inc.
$189
Takeda Pharmaceuticals U.S.A., Inc.
$176
GlaxoSmithKline, LLC.
$149
Incyte Corporation
$132
SOBI, INC
$125
E.R. Squibb & Sons, L.L.C.
$107
Astellas Pharma US Inc
$100
GENZYME CORPORATION
$98
Exelixis Inc.
$95
SUN PHARMACEUTICAL INDUSTRIES INC.
$81
ABBVIE INC.
$74
Coherus Biosciences Inc.
$67
Mirati Therapeutics, Inc.
$67
Agios Pharmaceuticals, Inc.
$60
Genentech USA, Inc.
$57
Boehringer Ingelheim Pharmaceuticals, Inc.
$54
TAIHO ONCOLOGY, INC.
$49
Celgene Corporation
$48
Blueprint Medicines Corporation
$46
AstraZeneca Pharmaceuticals LP
$44
EMD Serono, Inc.
$38
Gilead Sciences, Inc.
$34
ADC Therapeutics America, Inc.
$34
Karyopharm Therapeutics Inc.
$34
SpringWorks Therapeutics, Inc.
$33
Tempus AI, Inc
$33
JAZZ PHARMACEUTICALS INC.
$31
Alexion Pharmaceuticals, Inc.
$30
Deciphera Pharmaceuticals Inc.
$29
Lilly USA, LLC
$28
Aveo Pharmaceuticals, Inc.
$28
ImmunoGen, Inc.
$27
Adaptive Biotechnologies Corporation
$23
Top 3 companies account for 24.3% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,302
PFIZER INC.
$1,292
Janssen Biotech, Inc.
$1,272
E.R. Squibb & Sons, L.L.C.
$704
GENZYME CORPORATION
$678
GlaxoSmithKline, LLC.
$583
Amgen Inc.
$570
Incyte Corporation
$540
Exelixis Inc.
$499
Bayer HealthCare Pharmaceuticals Inc.
$460
Daiichi Sankyo Inc.
$449
Takeda Pharmaceuticals U.S.A., Inc.
$401
AstraZeneca Pharmaceuticals LP
$396
Merck Sharp & Dohme LLC
$382
Eisai Inc.
$351
Athenex Pharmaceutical Division, LLC
$350
Astellas Pharma US Inc
$348
EMD Serono, Inc.
$337
Celgene Corporation
$322
Bayer Healthcare Pharmaceuticals Inc.
$305
COMSORT, Inc
$250
EISAI INC.
$241
Seagen Inc.
$212
SOBI, INC
$211
ABBVIE INC.
$202
Pharmacyclics LLC, An AbbVie Company
$192
Dova Pharmaceuticals
$189
Genentech USA, Inc.
$188
Karyopharm Therapeutics Inc.
$175
Clovis Oncology, Inc.
$162
Merck Sharp & Dohme Corporation
$159
Gilead Sciences, Inc.
$157
Sobi, Inc
$146
Lilly USA, LLC
$138
TOLMAR Pharmaceuticals, Inc.
$129
Agios Pharmaceuticals, Inc.
$118
Deciphera Pharmaceuticals Inc.
$112
Boehringer Ingelheim Pharmaceuticals, Inc.
$99
TAIHO ONCOLOGY, INC.
$97
Coherus Biosciences Inc.
$93
ImmunoGen, Inc.
$92
Regeneron Healthcare Solutions, Inc.
$89
Alexion Pharmaceuticals, Inc.
$87
SANOFI-AVENTIS U.S. LLC
$82
SUN PHARMACEUTICAL INDUSTRIES INC.
$81
Organon LLC
$80
JAZZ PHARMACEUTICALS INC.
$76
Mirati Therapeutics, Inc.
$67
MorphoSys, US Inc.
$65
Teva Pharmaceuticals USA, Inc.
$60
Seattle Genetics, Inc.
$57
Foundation Medicine, Inc.
$56
ADC Therapeutics America, Inc.
$49
Blueprint Medicines Corporation
$46
PharmaEssentia USA Corporation
$43
TESARO, Inc.
$37
Myriad Genetic Laboratories, Inc.
$36
SpringWorks Therapeutics, Inc.
$33
Tempus AI, Inc
$33
Sun Pharmaceutical Industries Inc.
$31
Dendreon Pharmaceuticals LLC
$28
Aveo Pharmaceuticals, Inc.
$28
Alnylam Pharmaceuticals Inc.
$27
Stemline Therapeutics Inc.
$27
EUSA Pharma (US) LLC
$26
Apellis Pharmaceuticals, Inc.
$25
Puma Biotechnology, Inc.
$24
Adaptive Biotechnologies Corporation
$23
Taiho Oncology, Inc.
$22
PUMA BIOTECHNOLOGY, INC.
$22
Sirtex Medical Inc
$19
Janssen Pharmaceuticals, Inc
$18
Global Blood Therapeutics, Inc.
$18
Advanced Accelerator Applications
$16
GE HealthCare
$15
Otsuka America Pharmaceutical, Inc.
$15
ARRAY BIOPHARMA INC
$14
Top 3 companies account for 23.6% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Aranesp · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ENHERTU · ENJAYMO · ERLEADA · EVENITY · Elahere · Empaveli · Enhertu · Erleada · FOTIVDA · FOUNDATIONONE CDX · FRUZAQLA · Fabhalta · GAMIFANT · GILOTRIF · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEMPERLI · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Orserdu · PADCEV · PIQRAY · PROMACTA · PROVENGE · PYRUKYND · Pomalyst · Prolia · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SPRYCEL · SUTENT · SYNAGIS · Stivarga · Sylvant · TAGRISSO · TALVEY · TASIGNA · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VYXEOS · Venclexta · XALKORI · XARELTO · XPOVIO · XT CDX · XTANDI · Xofigo · Xospata · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZYTIGA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
406
Per 100K population
4.1
County median income
$87,760
Nearest hospital
PIH HEALTH GOOD SAMARITAN HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Orr is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Orr experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Orr performed 4,560 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Orr receive payments from pharmaceutical companies?
Yes. Dr. Orr received a total of $16,377 from 77 companies across 708 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Orr's costs compare to other hematology & oncology specialists in Los Angeles?
Dr. Orr's average Medicare payment per service is $24. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Orr) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Los Angeles
Browse hematology & oncology specialists in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology